“For this particular medication, patients who have a genetic mutation called EGFRm — and who have already had surgery — are viable candidates for Tagrisso.”
(Melissa Rudy) Many lung cancer patients now have access to a potentially life-saving medication.
Osimertinib, sold under the brand name Tagrisso, is available to patients with Stage 1B-3A lung cancer who have a certain genetic mutation and have had surgery to remove cancerous tumors.
Among those patients, Tagrisso was shown to reduce the five-year risk of recurrent cancer by up to 73% and the risk of death by up to 51%, according to research published in The New England Journal of Medicine over the summer.